European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading
BioNTech SE's (NASDAQ:BNTX) Largest Shareholders Are Private Equity Firms With 43% Ownership, Insiders Own 19%
CCORF Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $171
H.C. Wainwright Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $113
Buy Rating Affirmed for BioNTech SE on Strong Phase 2 Results and Positive Valuation
Breakthrough again for tumor mRNA vaccine. Biontech's (BNTX.US) Phase II clinical trial for advanced melanoma is a success.
On July 30th, Biontech (BNTX.US) announced that the Phase II clinical study of BNT111+mRNA vaccine for tumors combined with PD-1 treatment achieved the main endpoint of ORR in unresectable Stage III or IV melanoma patients who progressed after PD-1 treatment.
Health Care Flat on Mixed Earnings - Health Care Roundup
BioNTech's Skin Cancer Combo Shrinks Tumors in Mid-stage Study
BioNTech Posts Mid-stage Win for MRNA Cancer Drug With Regeneron's Libtayo
Today's Morning Movers and Top Ratings: CRWD, PFE, PYPL, DEO and More
Pfizer Stock Gains After Raising Annual Outlook
BioNTech Immunotherapy Drug Candidate Shows Promise in Mid-Stage Trial
BioNTech's Cancer Drug Meets Primary Endpoint in Phase 2 Trial
Express News | BioNTech Reports Topline Data From Ongoing Phase 2 Clinical Trial For MRNA Immunotherapy Candidate BNT111 For Advanced Melanoma; Trial Met Its Primary Efficacy Outcome Measure
BioNTech SE (BNTX) Receives a Hold From Morgan Stanley
MHRA Approves Pfizer-BioNTech's Comirnaty JN.1 Vaccine
Pfizer, BioNTech Covid Vaccine Receives Approval in UK
Pfizer/ BioNTech Win U.K. Nod for JN.1-adjusted COVID-19 Shot
Express News | UK's MHRA Approved An Adapted Pfizer/BioNTech Covid-19 Vaccine (Comirnaty) That Targets The JN.1 Covid-19 Subvariant; Four Forms Of This Adapted Comirnaty JN.1 Vaccine Have Been Approved
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading